Pharmacogenomics and Personalized Medicine in Neuropsychiatry

Pharmacogenomics approach in psychiatry disorders

Psychiatric disorders are important health issues in the world, and their management is facing some serious challenges. Drugs that are widely used in the treatment of psychiatric disorders, including antidepressants, antipsychotics, and mood stabilizers, are often associated with many side effects and are adequately effective only in a small proportion of patients. Many factors, including genet...

Pharmacogenomics of glibenclamide in patients with type 2 diabetes mellitus: A systematic review

Introduction: One of the most widely used anti-diabetic drugs is sulfonylureas, which is often used as one of the first-line drugs in the treatment of type 2 diabetes. Due to the effect of the patient's genetic structure on the drug response (personalized medicine), the identification of genetic variations not only reduces the rate of adverse drug reactions but can also predict the effectivenes...

A Conceptual model on the pharmacogenomics implementation complications: An applied qualitative research based on national drug policy components

Introduction: Pharmacogenomics may well have substantial effects on the clinical, economic and regulatory aspects of health sector; which can lead to complications in access. Therefore, there is a need for evidence-based frameworks based on national drug policy components. The objective of the current study is to identify pharmacogenomics-based complications and develop a conceptual model. Mate...

Public Health Pharmacogenomics and the Design Principles for Global Public Goods - Moving Genomics to Responsible Innovation.

Ozdemir, Vural; Borda-Rodriguez, Alexander; Dove, Edward S; Ferguson, Lynette R; Huzair, Farah; Manolopoulos, Vangelis G.; Masellis, Mario; Milius, Djims; Warnich, Louise and Srivastava, Sanjeeva (2013). Editorial: public health pharmacogenomics and the design principles for global public goods – moving genomics to responsible innovation. Current Pharmacogenomics and Personalized Medicine, 11(1...

End of the Beginning and Public Health Pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine.